Trade the Expected Move
Apr 17 • Expiry
CRVS price in 14 days?
News
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments.
seekingalpha.com • Mar 28, 2025 09:30 Eastern
Corvus Pharmaceuticals: Now At Cruising Altitude
Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising developments, including a Phase 2 trial for autoimmune lymphoproliferative syndrome and potential solid tumor trials, but current data is inconclusive. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued.
seekingalpha.com • Mar 28, 2025 09:29 Eastern
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Jeff Jones - Oppenheimer Aydin Huseynov - Ladenburg Thalmann Cha Cha Yang - Jefferies Daniel Bronder - Cantor Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
seekingalpha.com • Mar 25, 2025 19:58 Eastern
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m.
globenewswire.com • Mar 25, 2025 16:01 Eastern
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum
globenewswire.com • Mar 20, 2025 08:00 Eastern
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET.
globenewswire.com • Mar 19, 2025 16:01 Eastern
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
globenewswire.com • Mar 17, 2025 16:01 Eastern
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has initiated a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease.
globenewswire.com • Mar 12, 2025 08:00 Eastern